Komori
General Meetings of Shareholders4502Takeda Pharmaceutical Company LimitedPharmaceuticals

Other Matters Subject to Electronic Provision for the 150th Annual General Meeting of Shareholders

The consolidated notes and non-consolidated notes attached to the notice of convocation for the 150th Annual General Meeting of Shareholders were disclosed as matters subject to electronic provision.

Worth reading
19Immaterial
Scored from 3 of 4 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (150th)
2026
Jun 24
Date and time(start time: Not disclosed)28 days from this disclosure to the meeting
Matters for resolution1 item
  1. Matters relating to dividends on common shares (total dividends: ¥158,494 million; dividend per share: ¥100; record date: 31 March 2026; effective date: 25 June 2026)

Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (150th)
Date and time24 June 2026 (start time: Not disclosed)
Matters for resolutionMatters relating to dividends on common shares (total dividends: ¥158,494 million; dividend per share: ¥100; record date: 31 March 2026; effective date: 25 June 2026)
Items this document does not state (3)
Shareholder ProposalDirector nomineePercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To provide the notes to the consolidated financial statements and financial statements as other matters subject to electronic provision relating to the Annual General Meeting of Shareholders.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Other Matters Subject to Electronic Provision for the 150th Annual General Meeting of Shareholders | Takeda Pharmaceutical Company Limited (4502) timely disclosure | Komori